Shared Decision Making for HER2-Negative Metastatic Breast Cancer
Part of Cancer, Skin clinical trials.
This study helps patients with HER2-negative metastatic breast cancer (cancer that has spread beyond the breast) make informed treatment choices together with their doctors. The trial focuses on how shared decision-making—where you and your care team discuss options together—affects your care experience and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with metastatic breast cancer (cancer that has spread to other parts of your body)
- Your cancer is HER2-negative (a specific protein marker that doctors test for)
- You are starting or have recently started your first treatment for metastatic disease
- You are 18 years old or older
- You are willing to sign a consent form and participate in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an educational program designed to help women with metastatic breast cancer (cancer that has spread) improve their sexual health and function. The program focuses on addressing sexual concerns that often arise during cancer treatment.
This study tests a decision aid to help women 70 and older with early stage breast cancer choose their treatment. It looks at whether the tool helps patients and their doctors make a confident treatment choice.
This trial tests a group-based lifestyle program for women with HR+/HER2- metastatic breast cancer. The program helps you improve diet, increase physical activity, and learn mind-body practices in a supportive group setting.
This trial is testing a decision aid to help women newly diagnosed with breast cancer choose between different surgery options. It looks at how well this tool supports you in making a choice that fits your values and preferences.
This study tests a new treatment combining two drugs (SSGJ-612 and an antibody-drug) for people with a certain type of advanced breast cancer (hormone receptor-positive and HER2-low or ultra-low). The goal is to see if this combination can help when endocrine therapy has stopped working.
This study looks at treatment choices for adults with breast cancer that has spread and cannot be removed by surgery (unresectable metastatic disease). It focuses on people with HER2-low (and some HER2-ultralow) and/or hormone-receptor positive cancer, and compares how well treatments like T-DXd or standard chemotherapy work.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.